This is a standard, non-material filing. Traders should note that the vote is a routine governance matter and does not signal any change in the company's strategy, financial outlook, or operations. No trading action is required based on this filing alone.
Price Chart
Executive Summary
Zenas BioPharma, Inc. (ZBIO) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for May 11, 2026. The meeting will be held virtually, and shareholders are asked to vote on two proposals: the election of two Class II director nominees (James Boylan and Patrick Enright) and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for 2026.
Key Facts
- The filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting of Zenas BioPharma, Inc. (ZBIO).
- The meeting will be held virtually on May 11, 2026.
- Two proposals are on the ballot: (1) Electing two Class II director nominees (James Boylan and Patrick Enright) and (2) Ratifying Ernst & Young LLP as the independent auditor for 2026.
- The board recommends voting 'FOR' both proposals.
- The filing is routine and administrative, with no new financial data, strategic announcements, or material changes disclosed.
Financial Impact
No direct financial impact. Routine administrative filing.
Risk Factors
- None identified. The filing contains no new risks or disclosures.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-028064 |
| Document: 0001104659-26-028064-index-headers.html | 0001104659-26-028064 |
| Document: 0001104659-26-028064-index.html | 0001104659-26-028064 |
| Document: 0001104659-26-028064.txt | 0001104659-26-028064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Press Release | $26.71 | awaiting T+60 | — | $27.24 (+1.98%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.24 (+8.27%) |
Sep 22, 2026 4w ago | Press Release | $33.05 | awaiting T+60 | — | $27.24 (−17.58%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.24 (−16.31%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.24 (−14.63%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.24 (+46.77%) |
May 19, 2026 22w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.24 (+52.69%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers